Clinical trials: Multiple Sclerosis (Relapsing Remitting)
Multiple Sclerosis
Combination Therapy of Betaseron-Prograf in Multiple Sclerosis
The purpose of the study is to evaluate the safety and tolerability of a combination of interferon beta 1-b (Betaseron®) and tacrolimus (Prograf®) in patients suffering from multiple sclerosis (MS) who have failed treatment with…
- Trial name
- NCT00298662
- Testing
- Interferon beta-1b and Tacrolimus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Clinique de sclérose en plaques et neuromusculaire de l'Outaouais
Multiple Sclerosis, Relapsing-Remitting
Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis
Our project proposal is based on an individualized rehabilitation approach in patients with early stage relapsing remission (RR) MS.
- Trial name
- RELIABLE (NCT06303024)
- Testing
- personalized combined physical and cognitive intervention
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Relapsing-Remitting Multiple Sclerosis
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
Data on fingolimod effects on NK cells are so far conflicting. A longitudinal study on fingolimod treated kidney transplant patients showed that NK cells were not influenced in any of the treatment groups.
- Trial name
- NCT01790269
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Charite University, Berlin, Germany
Relapsing Remitting Multiple Sclerosis
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg).
- Trial name
- SURPASS (NCT01058005)
- Testing
- BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 84 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS)
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis
- Trial name
- NCT07006805
- Testing
- CABA-201
- Sponsor
- Cabaletta Bio
Relapsing Remitting Multiple Sclerosis
An Extension of the TG1101-RMS201 Trial
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
- Trial name
- NCT03381170
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- TG Therapeutics, Inc.
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal stem cell transplantation, involving approximately 24 ambulatory participants with relapsing forms of MS (approximately equal numbers…
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT00813969
- Testing
- Autologous mesenchymal stem cell transplantation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The Cleveland Clinic
Relapsing-remitting Multiple Sclerosis
Sensori-motor Integration Training in Multiple Sclerosis
Balance impairment is a common and very disabling disturbance in people with Multiple Sclerosis. The efficacy of pharmacotherapy in treating balance impairment in MS is poorly documented in literature.
- Trial name
- NCT01040117
- Testing
- Sensory-motor Integration Training, Conventional neurorehabilitation treatment
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- Universita di Verona
Multiple Sclerosis, Relapsing-remitting
A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina
This is an observational, non-controlled, multicentric, prospective study planned to be conducted in 66 subjects diagnosed with multiple sclerosis (MS) in 20 centres of Argentina.
- Trial name
- NCT01080001
- Where
- Argentina
- Volunteers
- 71 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
Impaired short term memory, attention and concentration lapses, and slower processing of information occur in up to 40-65% of patients with Multiple Sclerosis (MS).
- Trial name
- NCT00398528
- Testing
- Glatiramer acetate, (Copaxone®), IFN-β-1a, (Avonex®)
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Neurognostics
Multiple Sclerosis
RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.
- Trial name
- TRANSPLANTPRO (NCT06267781)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis
The aim of this monocentric randomized controlled intervention study is to improve visual function in persons with multiple sclerosis following optic neuritis (neuritis nervi optici) by means of a light stimulation.
- Trial name
- ONSTIM (NCT06389968)
- Testing
- Light stimulation
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Multiple Sclerosis, Clinically Isolated Syndrome
Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
This project aims to analyze ocular motility problems, visual processing speed and microperimetry, and their relationship with consolidated retinal structural biomarkers (optical coherence tomography, OCT) in patients with…
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
- Trial name
- NCT05706220
- Testing
- Eye tracking, Microperimetry, Optical coherence tomography (OCT)
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Multiple Sclerosis, Relapsing-Remitting
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
Natalizumab (NTZ) use in Multiple Sclerosis (MS) in highly active patients has been largely established during the last Rationale 10 years in both clinical trials and real-world practice.
- Trial name
- RELEVANT (NCT04580381)
- Testing
- Natalizumab Injection [Tysabri]
- Where
- 5 sites in France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Caen
Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
- Trial name
- NCT04940065
- Testing
- Kesimpta
- Where
- 103 sites in Japan
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
This study is to find out if there is any benefit to adding Simvastatin to Interferon-beta-1a in patients with Multiple Sclerosis.
- Trial name
- SIMCOMBIN (NCT00492765)
- Testing
- Interferon-beta-1a, Simvastatin
- Where
- Denmark
- Volunteers
- 380 people
- Sponsor
- Biogen
Multiple Sclerosis
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
The primary objective of this study is to define the effect of Tysabri in patients with relapsing-remitting (RR) multiple sclerosis (MS) over 2 years.
- Trial name
- NCT00937677
- Testing
- Tysabri
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Patient Experiences of Multiple Sclerosis (PExMS)
Besides coping with the diagnosis, people with multiple sclerosis have to make complex decisions such as deciding about immunotherapies.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Patient Engagement, Self Efficacy
- Trial name
- PExMS (NCT04236544)
- Testing
- PExMS and DECIMS-Wiki, DECIMS-Wiki
- Volunteers
- 55 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Relapsing-Remitting Multiple Sclerosis (RRMS)
Plegridy Satisfaction Study in Participants
The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with injectable subcutaneous Interferons, as…
- Trial name
- PLATINUM (NCT02587065)
- Testing
- peginterferon beta-1a
- Where
- 30 sites in Italy
- Volunteers
- 193 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multicenter study conducted in 2 parts: The primary objective in Part I of this study is to determine the efficacy of BG00012 (dimethyl fumarate, DMF) on inflammatory brain magnetic resonance imaging (MRI) lesion…
- Trial name
- NCT01838668
- Testing
- dimethyl fumarate
- Where
- 54 sites in Czechia, Japan and 3 more
- Volunteers
- 225 people
- Sponsor
- Biogen